- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04274842
D-OCT of Facial Telangiectasia Treated With IPL
Dynamic Optical Coherence Tomography Imaging of Telangiectasia Prior to Intense Pulsed Light Treatment - an Opportunity to Target Treatment?
Objectives: To examine whether dynamic Optical Coherence Tomography (OCT) could characterize vessel dimensions and blood flow of telangiectasias before and after treatment with Intense Pulsed Light (IPL).
Methods: Dynamic-OCT (D-OCT) imaged telangiectasia characterized blood vessel width and depth, blood flow, and attenuation. Measurements were done immediately before and after, 1-3 days after, and 1 month after IPL treatment. Characterization of vessel dimensions at baseline were verified by a blinded observer. At one-month follow-up, clinical improvement was characterized as good, moderate or none and possible adverse effects were described.
Study Overview
Detailed Description
Introduction Telangiectasia of the face are a common facial cosmetic disorder and may cause severe psychological distress. Facial telangiectasia may be treated with pulsed dye laser (PDL) or intense pulsed light (IPL). Clinical results are not always satisfactory and numerous treatments may be necessary to achieve acceptable results. Unexperienced operators often depend on treatment guidelines provided by the manufacturer when selecting energy settings for treatment, while more experienced operators may be guided by the immediate post-treatment biological endpoints and history of adverse events from previous treatment sessions. Thus, several treatments are often needed to determine optimal energy settings for the individual patient.
In general, light energy must be targeted to individual blood vessel dimensions, when optimizing laser or IPL treatment of vascular lesions. In clinical practice it may however be challenging to decide vessel width, vessel depth and blood flow by merely looking at the skin.
Optical coherence tomography (OCT) is a non-invasive in vivo imaging technique, which provides images of superficial skin structures. It has previously been demonstrated that OCT can visualize facial telangiectasias before and after IPL treatment. Dynamic OCT (D-OCT) adds identification and measurement of superficial cutaneous blood vessels with great certainty. Therefore, the aim of this study was to investigate whether D-OCT could be utilized to characterize vessel dimensions and blood flow of facial telangiectasias before and after IPL treatment.
Material and Methods Patients with telangiectasias visiting the Department of Dermatology for IPL treatment of telangiectasia at the Zealand University Hospital, Roskilde, between February and November 2018 were offered participation after informed consent. The study was approved by the Science Ethics Committee of Region Zealand (Approval no.: SJ-651) and the Danish Data Protection Agency (Approval no.: REG-177-2017).
D-OCT imaging was done immediately before, 1-3 days after, and one month after scheduled IPL treatment. The D-OCT scans and IPL treatments were performed by two separate physicians and the treating physician was blinded to all information obtained by D-OCT.
The IPL treatments were performed using a Palomar ICONTM Laser and Intense Pulsed Light platform applying a MaxGTM Optimized Handpiece with a dual-band wavelength of 500-670 nm and 870-1200 nm.
Dynamic OCT scans were performed by the 1305 nm VivoSight DX (Michelson Diagnostics, Kent, UK) with penetration depth of approximately 1 mm and vertical/horizontal optical resolution of less than 5/7.5 µm, respectively.
Drawn templates of appropriate facial telangiectasia ensured consistency of consecutive scans. Measurements of vessel dimensions were performed at the most evident level at horizontal images and verified by a blinded observer (PLA). A blinded (PLA) as well as an un-blinded evaluator (EHT) characterized vascular morphology at horizontal images from baseline and one-month follow-up. Clinical observations at one-month follow-up included changes in facial telangiectasia and registration of any adverse effects.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Roskilde, Denmark, 4000
- Zealand University Hospital Roskilde
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- legally competent,
- at least 18 years of age
- persons able to read and understand spoken and written information in Danish or English.
- One or more facial telangiectasia
Exclusion Criteria:
- wounds or ulcers in area of facial telangiectasia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: D-OCT image observational
Patients clinically eligible for IPL treatment of facial telangiectasia were D-OCT scanned before, after, 1-3 days after and 1 month after treatment
|
observation by D-OCT before, after, 1-3 days after, and 1 month after IPL treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
vessel width dimension
Time Frame: one-month follow-up
|
measurement of vessel width on D-OCT images
|
one-month follow-up
|
vessel depth dimension
Time Frame: one-month follow-up
|
measurement of vessel depth on D-OCT images
|
one-month follow-up
|
vessel blood flow
Time Frame: one-month follow-up
|
measurement of vessel blood flow on D-OCT images
|
one-month follow-up
|
Attenuation
Time Frame: one-month follow-up
|
measurement of attenuation on D-OCT images
|
one-month follow-up
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relation of D-OCT detected vessel dimensions to clinical efficacy
Time Frame: one-month follow-up
|
Clinical efficacy detected as good, moderate or none
|
one-month follow-up
|
Relation of D-OCT detected vessel dimensions to adverse effects
Time Frame: one-month follow-up
|
Description of adverse effects
|
one-month follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gregor BE Jemec, DmSc, Prof., Zealand University Hospital - Roskilde
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SJ-651
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Telangiectasia
-
The Lowy Medical Research Institute LimitedActive, not recruiting
-
Neurotech PharmaceuticalsCompletedMacular TelangiectasiaUnited States, Australia
-
Neurotech PharmaceuticalsThe Lowy Medical Research Institute LimitedCompletedIdiopathic Juxtafoveal TelangiectasiaUnited States
-
Paul S. BernsteinCompletedIdiopathic Juxtafoveal TelangiectasiaUnited States
-
Centre Hospitalier Universitaire DijonRecruitingMacular TelangiectasiaFrance
-
National Eye Institute (NEI)CompletedMacular TelangiectasiaUnited States
-
Vaderis Therapeutics AGRecruitingHereditary Hemorrhagic Telangiectasia (HHT)United States, Spain, France, Belgium, Netherlands, Italy
-
The Lowy Medical Research Institute LimitedActive, not recruitingMacular Telangiectasia Type 2United States, United Kingdom
-
Neurotech PharmaceuticalsCompletedMacular Telangiectasia Type 2United States, Australia, Germany
-
Neurotech PharmaceuticalsCompletedA Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol AMacular Telangiectasia Type 2United States, United Kingdom, Australia, France
Clinical Trials on observation by D-OCT
-
Centre Hospitalier William Morey - Chalon sur SaôneCentre Hospitalier Universitaire DijonRecruitingCritically Ill | Central Venous Catheter Associated Bloodstream Infection | Healthcare Associated InfectionFrance
-
Abbott Medical DevicesAbbottCompletedCoronary Artery Disease | Atherosclerosis | Coronary Stenosis | STEMI | NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial InfarctionUnited States, Spain, Australia, United Kingdom, Canada, New Zealand, Denmark, Switzerland, Germany, Netherlands, India, Japan, Italy, Belgium, France, Hong Kong, Portugal, Singapore, Sweden, Taiwan
-
University of MiamiWithdrawn
-
SIS Medical AGSuspendedCoronary Artery Disease | Coronary RestenosisSwitzerland
-
Hillel Yaffe Medical CenterUnknown
-
Istituto Clinico HumanitasNot yet recruitingHand Injuries | Motor Imagery | Action Observation
-
Intermountain Health Care, Inc.Completed
-
Abbott Medical DevicesCardiovascular Research Foundation, New YorkCompletedCoronary Artery DiseaseUnited States, Spain, Japan, United Kingdom, Germany, Belgium, Italy, Netherlands
-
Josue Fernandez CarneroCentro Universitario La SalleCompleted
-
University of BernSwiss National Science FoundationCompleted